All In Biotech

Drug Trial Radar · NCT02204644

The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML

Randomized, Multi-center, Open-label Phase III Study of the Efficacy and Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia.

Last checked: Nov 19, 2026Latest source record: Feb 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

400

Actual

Start

Jun 2014

Primary completion

Jun 2017

Study completion Dec 2017

Sponsor

Sponsor type
Industry
First posted
Jul 30, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to observe the efficacy and the safety of Flumatinib vs Imatinib as first line treatment in patients with newly diagnosed chronic phase chronic myelogenous leukemia. Randomized,Open Label,Control

Conditions

  • CML, CML-CP,MMR,TKI

Interventions

  • Flumatinib 600mg qdDrug

  • Imatinib 400mg qdDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SIX-month major molecular response rateTime frame: six months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital of Blood Diseases, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.